How to Implement Earlier Hepatitis B Treatment
Listen as Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, review strategies for more expansive HBV treatment while considering adverse events, cost-effectiveness, and patient perspectives.
Decera Clinical Education Infectious Disease Podcast · Mark S. Sulkowski MD FIDSA FAASLD, Tatyana Kushner MD MSCE, Paul Y. Kwo MD, Jacki Chen PhD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Mark S. Sulkowski, MD, FIDSA, FAASLD; Tatyana Kushner, MD, MSCE; Paul Y. Kwo, MD; and patient advocate Jacki Chen, PhD, consider barriers and solutions for more expansive HBV treatment in the United States. Topics include:
- Patient subgroups to consider for treatment outside guideline criteria
- Adverse event and cost-effectiveness considerations
- Integration of patient perspectives in wider treatment
Presenters:
Mark S. Sulkowski, MD, FIDSA, FAASLD
Professor of Medicine
Director, Division of Infectious Diseases, Johns Hopkins Bayview Medical Center
Johns Hopkins University School of Medicine
Baltimore, Maryland
Tatyana Kushner, MD, MSCE
Associate Professor
Division of Liver Diseases
Icahn School of Medicine at Mount Sinai
New York, New York
Paul Y. Kwo, MD
Professor of Medicine
Director of Hepatology
Stanford University School of Medicine
Palo Alto, California
Jacki Chen, PhD
Patient Advocate
Link to full program:
https://bit.ly/3TuqFHI
Link to the slides:
https://bit.ly/4a60GM4
Get access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.